Tianjin Ringpu Bio-TechnologyLtd Future Growth
Future criteria checks 2/6
Tianjin Ringpu Bio-TechnologyLtd is forecast to grow earnings and revenue by 17.7% and 16.9% per annum respectively. EPS is expected to grow by 17.4% per annum. Return on equity is forecast to be 12% in 3 years.
Key information
17.7%
Earnings growth rate
17.4%
EPS growth rate
Pharmaceuticals earnings growth | 19.0% |
Revenue growth rate | 16.9% |
Future return on equity | 12.0% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,742 | 764 | N/A | 691 | 5 |
12/31/2025 | 3,255 | 620 | 129 | 651 | 9 |
12/31/2024 | 2,761 | 530 | -415 | 437 | 7 |
3/31/2024 | 2,339 | 460 | 196 | 438 | N/A |
12/31/2023 | 2,249 | 453 | 134 | 378 | N/A |
9/30/2023 | 2,195 | 387 | 129 | 386 | N/A |
6/30/2023 | 2,170 | 385 | 156 | 462 | N/A |
3/31/2023 | 2,136 | 355 | 139 | 473 | N/A |
1/1/2023 | 2,084 | 347 | 17 | 389 | N/A |
9/30/2022 | 1,985 | 354 | -1 | 367 | N/A |
6/30/2022 | 1,875 | 349 | 0 | 317 | N/A |
3/31/2022 | 1,838 | 369 | -41 | 287 | N/A |
1/1/2022 | 2,007 | 413 | 77 | 383 | N/A |
9/30/2021 | 2,038 | 438 | 72 | 358 | N/A |
6/30/2021 | 2,117 | 454 | 87 | 408 | N/A |
3/31/2021 | 2,106 | 441 | 134 | 438 | N/A |
12/31/2020 | 2,000 | 398 | 129 | 388 | N/A |
9/30/2020 | 1,895 | 302 | 175 | 460 | N/A |
6/30/2020 | 1,737 | 255 | 183 | 417 | N/A |
3/31/2020 | 1,613 | 224 | 190 | 396 | N/A |
12/31/2019 | 1,467 | 194 | 154 | 384 | N/A |
9/30/2019 | 1,346 | 158 | 83 | 264 | N/A |
6/30/2019 | 1,260 | 137 | 56 | 216 | N/A |
3/31/2019 | 1,203 | 124 | 32 | 167 | N/A |
12/31/2018 | 1,190 | 119 | 62 | 175 | N/A |
9/30/2018 | 1,179 | 108 | 40 | 155 | N/A |
6/30/2018 | 1,157 | 117 | 45 | 159 | N/A |
3/31/2018 | 1,112 | 112 | 6 | 113 | N/A |
12/31/2017 | 1,047 | 105 | N/A | 110 | N/A |
9/30/2017 | 1,008 | 136 | N/A | 152 | N/A |
6/30/2017 | 993 | 138 | N/A | 155 | N/A |
3/31/2017 | 988 | 140 | N/A | 185 | N/A |
12/31/2016 | 970 | 133 | N/A | 208 | N/A |
9/30/2016 | 943 | 129 | N/A | 214 | N/A |
6/30/2016 | 905 | 113 | N/A | 221 | N/A |
3/31/2016 | 832 | 108 | N/A | 223 | N/A |
12/31/2015 | 793 | 110 | N/A | 225 | N/A |
9/30/2015 | 690 | 68 | N/A | 172 | N/A |
6/30/2015 | 639 | 43 | N/A | 131 | N/A |
3/31/2015 | 625 | 34 | N/A | 140 | N/A |
12/31/2014 | 585 | 27 | N/A | 130 | N/A |
9/30/2014 | 669 | 95 | N/A | 138 | N/A |
6/30/2014 | 676 | 113 | N/A | 136 | N/A |
3/31/2014 | 722 | 140 | N/A | 116 | N/A |
12/31/2013 | 755 | 152 | N/A | 89 | N/A |
9/30/2013 | 724 | 149 | N/A | 124 | N/A |
6/30/2013 | 702 | 148 | N/A | 100 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300119's forecast earnings growth (17.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 300119's earnings (17.7% per year) are forecast to grow slower than the CN market (24.4% per year).
High Growth Earnings: 300119's earnings are forecast to grow, but not significantly.
Revenue vs Market: 300119's revenue (16.9% per year) is forecast to grow faster than the CN market (14.6% per year).
High Growth Revenue: 300119's revenue (16.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300119's Return on Equity is forecast to be low in 3 years time (12%).